PDF(Pubmed)
Abstract：
Uveal melanoma (UM) is a rare type of melanoma with distinct features from cutaneous melanoma, low response rates to immune checkpoint inhibition, and poor survival rates. Tebentafusp, a bispecific antibody engaging T cells with gp 100 on HLA-A*02:01, was recently approved by the FDA as the first drug of its class and the first treatment approved by the FDA to treat UM. In this review, we summarize the preclinical and clinical data on tebentafusp for UM. We additionally discuss patient selection and the relevant challenges. For the literature search, PubMed search and relevant articles presented at international conferences were used.
摘要：
葡萄膜黑色素瘤（UM）是一种罕见的黑色素瘤，具有与皮肤黑色素瘤不同的特征，对免疫检查点抑制的低反应率，和低存活率。Tebentafusp,一种在HLA-A*02:01上与gp100结合的T细胞的双特异性抗体，最近被FDA批准为该类药物中的第一种，也是FDA批准用于治疗UM的第一种治疗方法。在这次审查中,我们总结了Tebentafusp治疗UM的临床前和临床数据。我们还讨论了患者选择和相关挑战。对于文献检索，使用了PubMed搜索和在国际会议上发表的相关文章。
